

HFU

patent attorneys

November 21, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 21, 2005.

Amy Yost
Amy Yost
Date of Signature: November 21, 2005

RICHARD E. JENKINS

JEFFREY L. WILSON

ARLES A. TAYLOR, JR.

GREGORY A. HUNT

E. ERIC MILLS

BENTLEY J. OLIVE

*CHRIS PERKINS, PH.D.

**JAMES DALY IV, PH.D.

JEFFREY CHILDERS, PH.D.

P. ASHLEY DARDEN

CHRISTOPHER B. LEE

TECHNICAL SPECIALIST
AMY ODENBAUGH, PH.D.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application Serial No. 10/635,265 for
NOVEL TARGETS FOR LITHIUM THERAPY
Our Ref. No. 180/158/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO-1449 (1 page) in duplicate;
3. Copies of cited references (4 references); and
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

*LICENSED ONLY IN CA


**LICENSED ONLY IN KY

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Arles A. Taylor, Jr.
Arles A. Taylor, Jr.
Registration No. 39,395

AAT/acy
Enclosures
Customer No: 25297



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 21, 2005.

PATENT

Amy Yost
Amy Yost
Date of Signature November 21, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: York et al. Group: 1632
Serial No.: 10/635,265 Examiner: Unknown
Filed: August 6, 2003 Docket No.: 180/158/2
Confirmation No.: 1379
For: NOVEL TARGETS FOR LITHIUM THERAPY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.


Serial No.: 10/635,265

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.


Date: 11/21/2005

By: 
Arles A. Taylor, Jr.
Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297



FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Application No.:	10/635,265
Filing Date:	August 6, 2003
First Named Inventor:	York
Group:	1632
Examiner:	To be assigned
Attorney Docket No.:	180/158/2

List of Documents Cited by Applicant

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
		International Search Report Corresponding to PCT patent application no. PCT/US03/24675 dated August 24, 2005.	
		SHALTIEL ET AL., "3'(2')-Phosphoadenosine 5'-phosphate phosphatase is reduced in postmortem frontal cortex of bipolar patients", <u>Bipolar Disorders</u> , 4 : 302-306, 2002.	
		SPIEGELBERG ET AL., "Cloning and Characterization of a Mammalian Lithium-Sensitive Bisphosphate 3'-Nucleotidase Inhibited by Inositol 1,4-Bisphosphate", <u>J. of Bio. Chem.</u> , 274(19) : 13619-13628, May 7, 1999.	
		YENUSH ET AL., "A novel target of lithium therapy", <u>FEBS</u> , 467 : 321-325, 2000.	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.